Evidence map›Paper›PMID 30046031›Full record

ArticleThe American journal of case reports2018

Effectivness of Clonidine in Treating Dexmedetomidine Withdrawal in a Patient with Co-Existing Psychiatric Illness: A Case Report.

Adham Mohamed, Sara Mahmoud, Mohamed O Saad, Khaled Gazwi, Moustafa Elshafei, Rasha Al Anany

Open access · hybridAbstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Adham MohamedDepartment of Pharmacy, Al Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Sara MahmoudDepartment of Pharmacy, Al Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Mohamed O SaadDepartment of Pharmacy, Al Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Khaled GazwiCritical Care Medicine Division, Department of Medicine, Al Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Moustafa ElshafeiCritical Care Medicine Division, Department of Medicine, Al Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Rasha Al AnanyDepartment of Pharmacy, Al Wakra Hospital, Hamad Medical Corporation, Doha, Qatar.
Hamad Medical Corporation · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Dexmedetomidine is a sedating agent approved for use in non-intubated patients and procedural sedation due to its efficacy in conscious sedation and minimal risks of respiratory depression. Previous reports proved the effectiveness of clonidine in treatment of withdrawal symptoms, but none have discussed cases with co-existing non-controlled psychiatric illness and prolonged duration of dexmedetomidine exposure. CASE REPORT We report a case of a 40-year-old woman diagnosed with viral meningitis. Due to her complicated psychiatric illness and viral meningitis, she developed severe agitation unresponsive to standard therapy. The patient had to be placed on dexmedetomidine, to which she developed dependence. There were several attempts to gradually withdraw dexmedetomidine but these were unsuccessful despite adding multiple antipsychotic medications. Withdrawal was manifested in multiple symptoms, including severe agitation, sweating, and tachycardia. Clonidine was used and was an effective treatment option to successfully withdraw the patient from dexmedetomidine. A smaller initial dose was used due to low baseline systolic blood pressure, which was successful. CONCLUSIONS This report proves that clonidine is an effective option for treatment of dexmedetomidine dependence compared to other antipsychotic agents. The present report is the first to discuss severe psychiatric illness and prolonged dexmedetomidine duration (>7 days) in a non-intubated patient. Dexmedetomidine withdrawal must be considered in the differential diagnosis of patients with psychiatric illness, which can be easily treated with clonidine.

Indexed as

AdultCentral Nervous System AgentsClonidineDexmedetomidineFemaleHumansHypnotics and SedativesMajor Depressive DisorderMeningitis, ViralSubstance Withdrawal SyndromeCentral Nervous System AgentsClonidineDexmedetomidineHypnotics and Sedatives

Identifiers

PMID30046031
PMCPMC6071494
OpenAlexW2883887504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.